Sanofi, the French multinational pharmaceutical company, is actively broadening its portfolio with recent acquisitions, including blueprint medicines for $9.5 billion and Vigil Neuroscience for $470 million. The investments aim at executing a strategic move into the rare disease and neurological disorder space. Sanofi also invested $25M in Adagene and has signed a €545M deal with Formation Bio. Its partnership with Abu Dhabi for vaccine development is a promising move, targeted to unleash global health benefits. Major breakthroughs are expected as multiple phase 2 trials like SAR444656 for Atopic Dermatitis and Hidradenitis Suppurativa are underway. There is ongoing research in fields like Multiple Myeloma, rheumatoid arthritis, and pediatric dermatology. Sanofi plans to invest at least $20B in the U.S. between 2025 to 2030 to expand drug research and manufacturing. Digital transformation and AI application to manufacturing and supply are facilitating faster and safer delivery to patients. Sustainable practices are also being promoted, enhancing environmental resilience. Great strides are being made in vaccine development for conditions like meningitis and Chlamydia.
Sanofi News Analytics from Mon, 23 Sep 2024 12:06:18 GMT to Sat, 12 Jul 2025 14:00:00 GMT -
Rating 8
- Innovation 7
- Information 8
- Rumor 1
